{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:botensilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zamerovimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03752398: Phase 1 Interventional Completed Melanoma (Excluding Uveal Melanoma)
(2019)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
INN:venanprubart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:abazistobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03524261: Phase 2 Interventional Withdrawn Advanced Breast Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab corixetan [INN]
Source URL:
Class:
PROTEIN